MDWD Logo

MediWound Ltd (MDWD) Stock Forecast & Price Prediction

Live MDWD Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Biotechnology

$19.50

+0.35 (1.83%)

12 Month Price Forecast For MDWD

$19.50
Current Price
$210.40M
Market Cap
4 Ratings
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MDWD Price Forecasts

+84.6%
To High Target of $36.00
+41.0%
To Median Target of $27.50
+28.2%
To Low Target of $25.00

MDWD Price Momentum

-1.9%
1 Week Change
+9.9%
1 Month Change
+73.0%
1 Year Change
+9.6%
Year-to-Date Change
-18.8%
From 52W High of $24.00
+76.6%
From 52W Low of $11.04

๐Ÿค” Considering MediWound (MDWD)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 5, 2025 12:47 PM UTC

MDWD Analyst Ratings & Price Targets

Based on our analysis of 9 Wall Street analysts, MDWD has a consensus that is bullish. The median price target is $27.50, with forecasts ranging from $25.00 to $36.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With MDWD currently trading at $19.50, the median price forecast suggests a 41.0% upside. The most optimistic forecast comes from at , projecting a 84.6% upside, while Swayampakula Ramakanth at HC Wainwright & Co. provides the most conservative target, suggesting a 28.2% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MDWD Analyst Consensus

4
Buy
0
Hold
0
Sell

MDWD Price Target Range

Low
$25.00
Average
$27.50
High
$36.00
Current: $19.50

Latest MDWD Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MDWD.

Date Firm Analyst Rating Change Price Target
Jan 10, 2025 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $25.00
Nov 27, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $25.00
Oct 11, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $28.00
Aug 15, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $28.00
Jul 16, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $28.00
May 30, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $28.00
Mar 22, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $28.00
Jan 16, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $28.00
Nov 22, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $26.00
Sep 21, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $26.00
Aug 17, 2023 HC Wainwright & Co. Buy Reiterates $0.00
Aug 17, 2023 Oppenheimer Outperform Maintains $0.00
May 31, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $23.00
May 31, 2023 Oppenheimer Francois Brisebois Outperform Reiterates $63.00
Mar 17, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $23.00
Jan 4, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $23.00
Dec 30, 2022 Cowen & Co. Joshua Jennings Outperform Maintains $25.00
Dec 22, 2022 Maxim Group Michael Okunewitch Buy Initiates $25.00
Dec 21, 2022 Oppenheimer Francois Brisebois Outperform Maintains $63.00
Nov 16, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $5.50

Stocks Similar to MediWound Ltd

The following stocks are similar to MediWound based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MediWound Ltd (MDWD) Financial Data

MediWound Ltd has a market capitalization of $210.40M with a P/E ratio of -26.0x. The company generates $20.14M in trailing twelve-month revenue with a -99.2% profit margin.

Revenue growth is +6.1% quarter-over-quarter, while maintaining an operating margin of -88.6% and return on equity of -75.7%.

Valuation Metrics

Market Cap $210.40M
Enterprise Value $138.07M
P/E Ratio -26.0x
PEG Ratio -8.8x
Price/Sales 10.4x

Growth & Margins

Revenue Growth (YoY) +6.1%
Gross Margin +15.5%
Operating Margin -88.6%
Net Margin -99.2%
EPS Growth N/A

Financial Health

Cash/Price Ratio +16.1%
Current Ratio 1.7x
Debt/Equity 35.6x
ROE -75.7%
ROA -15.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

MediWound Ltd logo

MediWound Ltd (MDWD) Company Overview

About MediWound Ltd

What They Do

Develops biopharmaceutical solutions for tissue repair.

Business Model

MediWound Ltd. generates revenue by developing and commercializing bio-therapeutic products aimed at tissue repair and regeneration. Its primary product, NexoBrid, is marketed to burn centers and hospitals for the treatment of thermal burns, while additional products like EscharEx and MW005 are in various stages of clinical development, targeting chronic wounds and cancer treatment respectively.

Additional Information

Founded in 2000 and headquartered in Yavne, Israel, MediWound operates in the biopharmaceutical sector with a focus on innovative solutions for wound care and tissue regeneration, addressing significant medical needs in both acute and chronic conditions.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

100

CEO

Country

Israel

IPO Year

2014

MediWound Ltd (MDWD) Latest News & Analysis

MDWD stock latest news image
Quick Summary

MediWound (MDWD) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.

Why It Matters

MediWound's share surge and above-average trading volume indicate heightened investor interest, but revised earnings estimates suggest potential price stabilization ahead.

Source: Zacks Investment Research
Market Sentiment: Positive
MDWD stock latest news image
Quick Summary

MediWound Ltd. (NASDAQ:MDWD) will hold its Q3 2024 Earnings Conference Call on November 26, 2024, at 8:30 AM ET, featuring key executives and analysts.

Why It Matters

The earnings call on November 26 will provide insights into MediWound's financial health and strategic direction, influencing stock performance and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Neutral
MDWD stock latest news image
Quick Summary

MediWound Ltd. plans to submit an IND for EscharEx by year-end and start a Phase 3 study. FDA approved NexoBrid for pediatric use, with strong product demand and financing to support operations.

Why It Matters

MediWound's IND submission and FDA approval for NexoBrid enhance growth prospects, while financing boosts cash flow, signaling potential profitability and strong demand for its products.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDWD stock latest news image
Quick Summary

MediWound (MDWD) reported a quarterly loss of $0.98 per share, wider than the estimated loss of $0.48, compared to a loss of $0.24 per share a year earlier.

Why It Matters

MediWound's larger-than-expected loss signals potential operational challenges, raising concerns about its financial health and future profitability, impacting investor confidence and stock performance.

Source: Zacks Investment Research
Market Sentiment: Negative
MDWD stock latest news image
Quick Summary

MediWound (MDWD) is seen as a long-term buy due to its innovative products and expected revenue growth, despite current losses. It has nearly doubled in price YTD and has strong investor backing.

Why It Matters

MediWound presents a potential growth opportunity despite current losses. Strong revenue projections, institutional backing, and a booming industry enhance its appeal to investors.

Source: Seeking Alpha
Market Sentiment: Positive
MDWD stock latest news image
Quick Summary

The company has secured new R&D collaborations with Solventum and Mรถlnlycke to enhance trial consistency and improve patient outcomes.

Why It Matters

New R&D collaborations can enhance product development, improve trial results, and potentially lead to market advantages, positively impacting future revenue and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About MDWD Stock

What is MediWound Ltd's (MDWD) stock forecast for 2025?

Based on our analysis of 9 Wall Street analysts, MediWound Ltd (MDWD) has a median price target of $27.50. The highest price target is $36.00 and the lowest is $25.00.

Is MDWD stock a good investment in 2025?

According to current analyst ratings, MDWD has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.50. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MDWD stock?

Wall Street analysts predict MDWD stock could reach $27.50 in the next 12 months. This represents a 41.0% increase from the current price of $19.50. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is MediWound Ltd's business model?

MediWound Ltd. generates revenue by developing and commercializing bio-therapeutic products aimed at tissue repair and regeneration. Its primary product, NexoBrid, is marketed to burn centers and hospitals for the treatment of thermal burns, while additional products like EscharEx and MW005 are in various stages of clinical development, targeting chronic wounds and cancer treatment respectively.

What is the highest forecasted price for MDWD MediWound Ltd?

The highest price target for MDWD is $36.00 from at , which represents a 84.6% increase from the current price of $19.50.

What is the lowest forecasted price for MDWD MediWound Ltd?

The lowest price target for MDWD is $25.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 28.2% increase from the current price of $19.50.

What is the overall MDWD consensus from analysts for MediWound Ltd?

The overall analyst consensus for MDWD is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.50.

How accurate are MDWD stock price projections?

Stock price projections, including those for MediWound Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.